title: Age dependence of brain β-amyloid deposition in Down syndrome: An [18F]florbetaben PET study.
abstract: OBJECTIVE
  To investigate brain β-amyloid binding in subjects with Down syndrome (DS) using [(18)F]florbetaben PET imaging.
  
  
  METHODS
  Thirty-nine subjects with DS (46.3 ± 4.7 years) were assessed with [(18)F]florbetaben PET imaging. Three blinded independent readers assessed the scans to provide a visual analysis. The primary quantitative imaging outcome was a standardized uptake value ratio (SUVR) obtained for 6 brain regions. Cognitive status was evaluated using the Dementia Screening Questionnaire for Individuals with Intellectual Disabilities (DSQIID).
  
  
  RESULTS
  [(18)F]Florbetaben uptake was correlated with age (p < 0.0001, R(2) = 0.39); 90% of scans in subjects with DS aged 50 years or older (SUVR = 1.62 ± 0.26), 53% in those aged 45 to 49 years (SUVR = 1.43 ± 0.16), and 7% in those aged 40 to 45 years (SUVR = 1.27 ± 0.11) were visually assessed as positive. Visual and quantitative assessments were highly related (χ(2) = 11.3823, p = 0.0007; Cohen κ = 0.58). Only 2 of 34 participants were considered to have dementia by the DSQIID.
  
  
  CONCLUSIONS
  Brain β-amyloid binding, as measured by [(18)F]florbetaben, increases with age in DS. Subjects with DS who have no evidence of dementia demonstrate brain β-amyloid binding in vivo, suggesting that [(18)F]florbetaben PET imaging may detect β-amyloid in this at-risk population.
authors.affiliation: From the Institute for Neurodegenerative Disorders (D.J., J.S., K.M.), New Haven, CT; Banner Sun Health Research Institute (M.S.), Sun City, AZ; McLean Hospital (F.L.), Belmont, MA; University of Vermont College of Medicine (W.H.), Burlington, VT; Piramal Imaging GmbH (S.B., A.S., A.M.C.), Berlin, Germany; MRI Research Unit (M.G.), Hospital del Mar, Barcelona, Spain; Navidea Biopharmaceuticals (C.R.) (formerly at Bayer Healthcare); and Bayer Healthcare (B.P.), Berlin, Germany. DJennings@indd.org.
authors.forename: Danna
authors.initials: D
authors.lastname: Jennings
authors.affiliation: From the Institute for Neurodegenerative Disorders (D.J., J.S., K.M.), New Haven, CT; Banner Sun Health Research Institute (M.S.), Sun City, AZ; McLean Hospital (F.L.), Belmont, MA; University of Vermont College of Medicine (W.H.), Burlington, VT; Piramal Imaging GmbH (S.B., A.S., A.M.C.), Berlin, Germany; MRI Research Unit (M.G.), Hospital del Mar, Barcelona, Spain; Navidea Biopharmaceuticals (C.R.) (formerly at Bayer Healthcare); and Bayer Healthcare (B.P.), Berlin, Germany.
authors.forename: John
authors.initials: J
authors.lastname: Seibyl
authors.affiliation: From the Institute for Neurodegenerative Disorders (D.J., J.S., K.M.), New Haven, CT; Banner Sun Health Research Institute (M.S.), Sun City, AZ; McLean Hospital (F.L.), Belmont, MA; University of Vermont College of Medicine (W.H.), Burlington, VT; Piramal Imaging GmbH (S.B., A.S., A.M.C.), Berlin, Germany; MRI Research Unit (M.G.), Hospital del Mar, Barcelona, Spain; Navidea Biopharmaceuticals (C.R.) (formerly at Bayer Healthcare); and Bayer Healthcare (B.P.), Berlin, Germany.
authors.forename: Marwan
authors.initials: M
authors.lastname: Sabbagh
authors.affiliation: From the Institute for Neurodegenerative Disorders (D.J., J.S., K.M.), New Haven, CT; Banner Sun Health Research Institute (M.S.), Sun City, AZ; McLean Hospital (F.L.), Belmont, MA; University of Vermont College of Medicine (W.H.), Burlington, VT; Piramal Imaging GmbH (S.B., A.S., A.M.C.), Berlin, Germany; MRI Research Unit (M.G.), Hospital del Mar, Barcelona, Spain; Navidea Biopharmaceuticals (C.R.) (formerly at Bayer Healthcare); and Bayer Healthcare (B.P.), Berlin, Germany.
authors.forename: Florence
authors.initials: F
authors.lastname: Lai
authors.affiliation: From the Institute for Neurodegenerative Disorders (D.J., J.S., K.M.), New Haven, CT; Banner Sun Health Research Institute (M.S.), Sun City, AZ; McLean Hospital (F.L.), Belmont, MA; University of Vermont College of Medicine (W.H.), Burlington, VT; Piramal Imaging GmbH (S.B., A.S., A.M.C.), Berlin, Germany; MRI Research Unit (M.G.), Hospital del Mar, Barcelona, Spain; Navidea Biopharmaceuticals (C.R.) (formerly at Bayer Healthcare); and Bayer Healthcare (B.P.), Berlin, Germany.
authors.forename: William
authors.initials: W
authors.lastname: Hopkins
authors.affiliation: From the Institute for Neurodegenerative Disorders (D.J., J.S., K.M.), New Haven, CT; Banner Sun Health Research Institute (M.S.), Sun City, AZ; McLean Hospital (F.L.), Belmont, MA; University of Vermont College of Medicine (W.H.), Burlington, VT; Piramal Imaging GmbH (S.B., A.S., A.M.C.), Berlin, Germany; MRI Research Unit (M.G.), Hospital del Mar, Barcelona, Spain; Navidea Biopharmaceuticals (C.R.) (formerly at Bayer Healthcare); and Bayer Healthcare (B.P.), Berlin, Germany.
authors.forename: Santi
authors.initials: S
authors.lastname: Bullich
authors.affiliation: From the Institute for Neurodegenerative Disorders (D.J., J.S., K.M.), New Haven, CT; Banner Sun Health Research Institute (M.S.), Sun City, AZ; McLean Hospital (F.L.), Belmont, MA; University of Vermont College of Medicine (W.H.), Burlington, VT; Piramal Imaging GmbH (S.B., A.S., A.M.C.), Berlin, Germany; MRI Research Unit (M.G.), Hospital del Mar, Barcelona, Spain; Navidea Biopharmaceuticals (C.R.) (formerly at Bayer Healthcare); and Bayer Healthcare (B.P.), Berlin, Germany.
authors.forename: Monica
authors.initials: M
authors.lastname: Gimenez
authors.affiliation: From the Institute for Neurodegenerative Disorders (D.J., J.S., K.M.), New Haven, CT; Banner Sun Health Research Institute (M.S.), Sun City, AZ; McLean Hospital (F.L.), Belmont, MA; University of Vermont College of Medicine (W.H.), Burlington, VT; Piramal Imaging GmbH (S.B., A.S., A.M.C.), Berlin, Germany; MRI Research Unit (M.G.), Hospital del Mar, Barcelona, Spain; Navidea Biopharmaceuticals (C.R.) (formerly at Bayer Healthcare); and Bayer Healthcare (B.P.), Berlin, Germany.
authors.forename: Cornelia
authors.initials: C
authors.lastname: Reininger
authors.affiliation: From the Institute for Neurodegenerative Disorders (D.J., J.S., K.M.), New Haven, CT; Banner Sun Health Research Institute (M.S.), Sun City, AZ; McLean Hospital (F.L.), Belmont, MA; University of Vermont College of Medicine (W.H.), Burlington, VT; Piramal Imaging GmbH (S.B., A.S., A.M.C.), Berlin, Germany; MRI Research Unit (M.G.), Hospital del Mar, Barcelona, Spain; Navidea Biopharmaceuticals (C.R.) (formerly at Bayer Healthcare); and Bayer Healthcare (B.P.), Berlin, Germany.
authors.forename: Barbara
authors.initials: B
authors.lastname: Putz
authors.affiliation: From the Institute for Neurodegenerative Disorders (D.J., J.S., K.M.), New Haven, CT; Banner Sun Health Research Institute (M.S.), Sun City, AZ; McLean Hospital (F.L.), Belmont, MA; University of Vermont College of Medicine (W.H.), Burlington, VT; Piramal Imaging GmbH (S.B., A.S., A.M.C.), Berlin, Germany; MRI Research Unit (M.G.), Hospital del Mar, Barcelona, Spain; Navidea Biopharmaceuticals (C.R.) (formerly at Bayer Healthcare); and Bayer Healthcare (B.P.), Berlin, Germany.
authors.forename: Andrew
authors.initials: A
authors.lastname: Stephens
authors.affiliation: From the Institute for Neurodegenerative Disorders (D.J., J.S., K.M.), New Haven, CT; Banner Sun Health Research Institute (M.S.), Sun City, AZ; McLean Hospital (F.L.), Belmont, MA; University of Vermont College of Medicine (W.H.), Burlington, VT; Piramal Imaging GmbH (S.B., A.S., A.M.C.), Berlin, Germany; MRI Research Unit (M.G.), Hospital del Mar, Barcelona, Spain; Navidea Biopharmaceuticals (C.R.) (formerly at Bayer Healthcare); and Bayer Healthcare (B.P.), Berlin, Germany.
authors.forename: Ana M
authors.initials: AM
authors.lastname: Catafau
authors.affiliation: From the Institute for Neurodegenerative Disorders (D.J., J.S., K.M.), New Haven, CT; Banner Sun Health Research Institute (M.S.), Sun City, AZ; McLean Hospital (F.L.), Belmont, MA; University of Vermont College of Medicine (W.H.), Burlington, VT; Piramal Imaging GmbH (S.B., A.S., A.M.C.), Berlin, Germany; MRI Research Unit (M.G.), Hospital del Mar, Barcelona, Spain; Navidea Biopharmaceuticals (C.R.) (formerly at Bayer Healthcare); and Bayer Healthcare (B.P.), Berlin, Germany.
authors.forename: Ken
authors.initials: K
authors.lastname: Marek
mesh_terms: D000328:Adult; D000367:Age Factors; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000814:Aniline Compounds / Q000378:metabolism*; D001921:Brain / Q000000981:diagnostic imaging / Q000378:metabolism*; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D004314:Down Syndrome / Q000000981:diagnostic imaging / Q000378:metabolism*; D005260:Female; D005462:Fluorine Radioisotopes / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods; D016037:Single-Blind Method; D013267:Stilbenes / Q000378:metabolism*
chemical_list: D016229:Amyloid beta-Peptides; D000814:Aniline Compounds; D005462:Fluorine Radioisotopes; D013267:Stilbenes; C527756:4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene